LONDON, July 14, 2020 /PRNewswire/ — Elsevier, a global leader in research publishing and information analytics, today announced that it is endorsing the Leiden Manifesto for Research Metrics, ten principles that guide best practice in metrics-based research assessment.
The Leiden Manifesto is a set of practical and action-oriented recommendations for those engaged in the evaluation of research, whether in the role of evaluator, those being evaluated, or those responsible for designing and delivering research metrics and indicators. Elsevier, working through its recently-launched International Center for the Study of Research (ICSR), will now strive to develop its research evaluation tools and services aligned with the recommendations of the Leiden Manifesto.
“The Leiden Manifesto is a distillation of best practice in research assessment. Abiding by these ten principles means that research evaluation can play an important role in the development of research and its interactions with society. I look forward to seeing Elsevier use the principles across its business,” said Professor Diana Hicks, School of Public Policy, Georgia Institute of Technology, lead author on the 2015 Leiden Manifesto, and ICSR Advisory Board member.
2019 CiteScore™ Metrics were announced on June 23, 2020, the latest assessment of thousands of peer-reviewed research journals, book series, conference proceedings and trade publications covered in Scopus. In addition, an improved calculation methodology was introduced to provide a more robust, fair and faster indicator of research impact. CiteScore Metrics already align with Leiden Manifesto Principles by being clear (Principle 4 – methodology is simple and easy to understand); transparent (Principle 5 – the data are freely available for verification purposes); and offered as a suite of indicators (Principle 9 – the CiteScore Metrics suite, offered alongside two other journal citation metrics). The revision of the calculation methodology embodies Principle 10 (scrutinize indicators regularly and update them) and in the improved approach CiteScore values are now rounded to one decimal place to avoid false precision (Principle 8).
ICSR President Dr. Andrew Plume added, “Elsevier has supported a similar set of principles to the Leiden Manifesto for many years. Taking this formal step means that our customers and the broader research community have clarity on how we will deliver improved research evaluation tools and indicators. I’m delighted we now have the opportunity to learn from everyone connected to the Leiden Manifesto, and to bring these principles to an even wider audience.”
About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Media contact
David Tucker
Elsevier Communications, Europe
+44-7920-536-160
d.tucker@elsevier.com
View original content:http://www.prnewswire.com/news-releases/elsevier-endorses-leiden-manifesto-to-guide-its-development-of-improved-research-evaluation-301092317.html
SOURCE Elsevier
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…